[{"id":"61af50c9-eb81-4f95-aa89-37849ac3c9be","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005879","created_at":"2021-01-17T23:51:42.337Z","updated_at":"2024-07-02T16:37:21.599Z","phase":"Phase 2","brief_title":"LY353381 in Preventing Breast Cancer in Women With Hyperplasia","source_id_and_acronym":"NCT00005879","lead_sponsor":"University of Kansas Medical Center","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arzoxifene (LY353381)"],"overall_status":"Completed","enrollment":" Enrollment 199","initiation":"Initiation: 08/01/2000","start_date":" 08/01/2000","primary_txt":" Primary completion: 07/01/2008","primary_completion_date":" 07/01/2008","study_txt":" Completion: 07/01/2008","study_completion_date":" 07/01/2008","last_update_posted":"2017-05-30"},{"id":"52033cea-4db4-4ed4-a10c-0a59a9dbab52","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005886","created_at":"2021-01-17T23:51:44.325Z","updated_at":"2024-07-02T16:37:26.542Z","phase":"Phase 1","brief_title":"Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer","source_id_and_acronym":"NCT00005886","lead_sponsor":"University of Kansas Medical Center","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Soltamox (tamoxifen citrate) • arzoxifene (LY353381)"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 07/01/2000","start_date":" 07/01/2000","primary_txt":" Primary completion: 08/01/2002","primary_completion_date":" 08/01/2002","study_txt":" Completion: 08/01/2002","study_completion_date":" 08/01/2002","last_update_posted":"2017-01-13"}]